Correlation between unproven therapies and delayed return-to-work for COVID-19-infected healthcare workers

Arch Environ Occup Health. 2024;79(1):45-56. doi: 10.1080/19338244.2024.2353264. Epub 2024 May 20.

Abstract

The objective of this study is to investigate factors influencing the time to return to work (RTW) of HealthCare Workers (HCW) infected with COVID-19 during the initial wave of the pandemic in a southern French university hospital. Data collection of 170 HCW (between March 16 to June 1, 2020) included demographic and professional information, clinical profiles, comorbidities, medical management, therapies and RT-PCR results. The mean time to RTW was 15.6 days. Multivariate analyses revealed that the time to RTW was shorter among laboratory and emergency workers, while it was longer for HCW aged 40 to 49 years, at higher risk of severe illness, with a delayed negative SARS-CoV-2 PCR or those treated with azithromycin and/or hydroxychloroquine. This study highlights diverse factors affecting HCW RTW post-COVID-19 infection, underscoring the importance of exercising caution in administering unproven therapies to HCW during the early stages of a novel infectious pandemic.

Keywords: Covid-19; healthcare workers; occupation health; occupational infection; return to work; unproven therapies.

MeSH terms

  • Adult
  • COVID-19* / epidemiology
  • Female
  • France / epidemiology
  • Health Personnel* / statistics & numerical data
  • Humans
  • Hydroxychloroquine / therapeutic use
  • Male
  • Middle Aged
  • Return to Work* / statistics & numerical data
  • SARS-CoV-2*
  • Time Factors

Substances

  • Hydroxychloroquine